Eon™ FR 1064 Full Abdomen Clinical Study Protocol

Dominion Aesthetic Technologies

Status

Completed

Conditions

Abdominal Obesity

Treatments

Device: Experimental: eonTM FR 1064 nm device

Study type

Interventional

Funder types

Industry

Identifiers

NCT04842110

D0000000151

Details and patient eligibility

About

This is a marketing study intended to provide additional data for marketing purposes for the eon™ FR is FDA 510(k) which has been cleared for non-invasive lipolysis of the abdomen to achieve disruption of adipocyte cells intended for non-invasive aesthetic use to achieve a desired aesthetic effect. This device is intended for individuals with a Body Mass Index (BMI) of 30 kg/m2 or less.

Enrollment

26 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subject is a healthy male or female > 18 years or older seeking treatment for unwanted fat in the abdomen.
Subject must be able to read, understand and sign the Informed Consent Form (ICF) in English.
Subject has sufficient thickness (≥ 25 mm) of adipose tissue on the abdomen area.
Study subjects must agree to maintain their current diet and weight (not gaining or losing greater than ±5 lbs.
Subject must be willing and able to adhere to the treatment and follow-up visit schedule.
Subject must be willing to have limited sun exposure for the duration of the study, including the follow-up period.
Subject is willing to have photographs and ultrasound measurements taken of the treated area, which will be de-identified in evaluations and may be used in presentations and/or publications.
Female subjects must be using medically acceptable form of birth control during the entire course of the study or may be post-menopausal, surgically sterilized.

Exclusion criteria

Aesthetic fat reduction procedure in the treatment area within the previous year.
Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in last 6 months
Unstable weight within the last 6 months (+ or - 3% weight change in the prior six months)
Subject has an infection, dermatitis or a rash in the treatment area.
Subject has tattoos or jewelry in the treatment area or within the treatment area site or photography frame.
Subject has a history of keloid scarring, hypertrophic scarring or of abnormal wound healing.
Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
Subject has a history of a known bleeding disorder.
Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light.
Subject has known collagen, vascular disease or scleroderma.
Subject has undergone a surgery or procedure in the treatment area within 6 months of treatment, which is still healing.
Subject suffers from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy.
Subject is undergoing systemic chemotherapy for the treatment of cancer.
Subject is using gold therapy for disorders such as rheumatologic disease or lupus.
Subject has participated in a study of another device or drug within three months prior to enrollment or during the study.
As per the investigator's discretion, the subject has any physical or mental condition which might make it unsafe for the subject to participate in this study.
Subject has ongoing use of steroids or secondary rheumatoid drugs.
Subject is actively taking psychotropic medications.